INCOME TAXES - Reconciliation of income taxes (Details) - USD ($)	12 Months Ended
Dec. 31, 2025	Dec. 31, 2024
Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]
Income tax benefit using U.S. federal statutory rate	$ (4,605,000)	$ (9,357,000)
State income taxes	(122,000)	136,000
Permanent nondeductible items
Orphan Drug Credit	(1,176,000)	(4,582,000)
Research and development credits	6,000	(811,000)
Change in valuation allowance	5,401,000	16,113,000
Warrant cost/Revaluation	(130,000)	(1,276,000)
Share-based compensation	617,000
Other	4,000	40,000
Other	5,000	(197,000)
Total		$ 66,000
Tax Jurisdiction of Domicile [Extensible Enumeration]	UNITED STATES	UNITED STATES
Effective Income Tax Rate Reconciliation, Percent [Abstract]
Income tax benefit using U.S. federal statutory rate	21.00%	21.00%
State income taxes	0.56%	(0.31%)
Permanent nondeductible items	0.00%	0.00%
Orphan Drug Credit	5.36%	10.28%
Research and development credits	(0.03%)	1.82%
Change in valuation allowance	(24.63%)	(36.15%)
Warrant cost/Revaluation	0.59%	2.86%
Share-based compensation	(2.81%)
Other	(0.02%)	(0.09%)
Other	(0.02%)	0.44%
Total	0.00%	(0.15%)

Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to permanent nondeductible items.

No definition available.